Carl N. Kraus - Jan 17, 2023 Form 4 Insider Report for Aceragen, Inc. (ACGN)

Role
Chief Medical Officer
Signature
/s/ Carl N. Kraus
Stock symbol
ACGN
Transactions as of
Jan 17, 2023
Transactions value $
$0
Form type
4
Date filed
1/19/2023, 08:46 PM
Previous filing
Sep 30, 2022
Next filing
Feb 2, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACGN Options (Right to Buy) Options Exercise +441K 441K Jan 17, 2023 Common Stock 441K $208.76 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On January 17, 2023, the Issuer's Series Z Non-Voting Convertible Preferred Stock, par value $0.01 per share ("Series Z Preferred Stock") converted into shares of common stock of the Issuer, par value $0.001 per share ("Common Stock"). By operation of the certificate of designation for the Series Z Preferred Stock, each share of Series Z Preferred Stock was converted into 1,000 shares of Common Stock for no consideration.
F2 The option vests 25% on October 25, 2022, and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date.
F3 Reflects a 1-for-17 reverse stock split, which became effective on January 17, 2023 at 4:59 pm Eastern Time.